TY - JOUR
T1 - Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes
T2 - The Current Landscape and Future Directions
AU - Sabile, Jean
AU - Pavletic, Steven
AU - Migdady, Yazan
N1 - Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Myelodysplastic syndromes (MDSs) are characterized by a clonal proliferation of hematopoietic stem cells with potential life-threatening cytopenia(s) and transformation to acute myeloid leukemia. Individualized risk stratification is evolving with new molecular models, such as the Molecular International Prognostic Scoring System, for better estimation of leukemic transformation and overall survival. The only potential cure for MDSs is allogeneic transplant, although it is underutilized in MDSs because of advanced patient age and multiple comorbidities. Optimization of transplant relies on improved identification of high-risk patients pretransplant, using targeted therapies leading to deeper molecular response, developing lower toxicity conditioning regimens, engineering better molecular tools for early detection and relapse monitoring, and adding maintenance treatment strategies for high-risk patients posttransplant. This review provides an overview of transplant in MDSs with updates, future directions, and role for novel therapies.
AB - Myelodysplastic syndromes (MDSs) are characterized by a clonal proliferation of hematopoietic stem cells with potential life-threatening cytopenia(s) and transformation to acute myeloid leukemia. Individualized risk stratification is evolving with new molecular models, such as the Molecular International Prognostic Scoring System, for better estimation of leukemic transformation and overall survival. The only potential cure for MDSs is allogeneic transplant, although it is underutilized in MDSs because of advanced patient age and multiple comorbidities. Optimization of transplant relies on improved identification of high-risk patients pretransplant, using targeted therapies leading to deeper molecular response, developing lower toxicity conditioning regimens, engineering better molecular tools for early detection and relapse monitoring, and adding maintenance treatment strategies for high-risk patients posttransplant. This review provides an overview of transplant in MDSs with updates, future directions, and role for novel therapies.
KW - Hematopoietic stem cell transplantation
KW - VEXAS
KW - myelodysplastic syndrome
UR - http://www.scopus.com/inward/record.url?scp=85159770195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159770195&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000662
DO - 10.1097/PPO.0000000000000662
M3 - Article
C2 - 37195774
AN - SCOPUS:85159770195
SN - 1528-9117
VL - 29
SP - 179
EP - 187
JO - Cancer Journal (United States)
JF - Cancer Journal (United States)
IS - 3
ER -